Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.13 -1.7%	$13.32	$9.57 ▼ $30.41	$2.09B	0.89	1.51 million shs	1.23 million shs
MRVI Maravai LifeSciences	$2.22 -3.5%	$2.07	$1.67 ▼ $11.16	$565.35M	0.19	2.36 million shs	2.24 million shs
NAMS NewAmsterdam Pharma	$17.61 -3.7%	$18.58	$14.06 ▼ $27.29	$1.93B	0.01	639,119 shs	274,673 shs
VCEL Vericel	$40.92 -1.1%	$42.09	$37.39 ▼ $63.00	$2.06B	1.31	409,371 shs	300,720 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	-3.69%	+13.42%	-23.97%	-39.82%
MRVI Maravai LifeSciences	0.00%	+5.71%	+7.25%	-45.99%	-79.91%
NAMS NewAmsterdam Pharma	0.00%	-6.73%	+0.80%	-5.17%	-10.06%
VCEL Vericel	0.00%	-3.67%	-0.41%	-21.31%	-18.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5185 of 5 stars	3.3	1.0	3.4	3.4	2.5	0.0
MRVI Maravai LifeSciences	4.0541 of 5 stars	4.1	1.0	4.4	2.1	0.8	1.3
NAMS NewAmsterdam Pharma	2.6346 of 5 stars	3.5	1.0	0.0	2.9	5.0	0.0
VCEL Vericel	2.6592 of 5 stars	3.5	1.0	0.0	3.4	0.8	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.67	Moderate Buy	$42.13	178.42% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	199.05% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	144.18% Upside
VCEL Vericel	3.00	Buy	$61.14	49.42% Upside

Current Analyst Ratings Breakdown

Latest MRVI, ARWR, VCEL, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	MRVI Maravai LifeSciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
5/13/2025	MRVI Maravai LifeSciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
4/11/2025	VCEL Vericel	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $51.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/25/2025	MRVI Maravai LifeSciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $5.00
3/21/2025	MRVI Maravai LifeSciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.83	N/A	N/A	$1.54 per share	9.82
MRVI Maravai LifeSciences	$241.86M	2.34	$0.05 per share	41.71	$3.14 per share	0.71
NAMS NewAmsterdam Pharma	$47.14M	41.02	N/A	N/A	$3.50 per share	5.03
VCEL Vericel	$238.54M	8.64	$0.01 per share	3,081.95	$4.73 per share	8.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	N/A
MRVI Maravai LifeSciences	-$119.03M	-$1.14	N/A	N/A	N/A	-81.13%	-6.61%	-3.45%	8/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
VCEL Vericel	-$3.18M	$0.03	682.11	93.00	N/A	1.56%	1.48%	0.96%	8/7/2025 (Estimated)

Latest MRVI, ARWR, VCEL, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
2/26/2025	Q4 2024	NAMS NewAmsterdam Pharma	-$0.48	-$0.95	-$0.47	-$0.95	$3.30 million	$12.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
MRVI Maravai LifeSciences	0.89	10.74	9.94
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
VCEL Vericel	N/A	4.61	4.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
MRVI Maravai LifeSciences	50.25%
NAMS NewAmsterdam Pharma	89.89%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
MRVI Maravai LifeSciences	0.63%
NAMS NewAmsterdam Pharma	20.84%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
MRVI Maravai LifeSciences	610	254.66 million	250.94 million	Optionable
NAMS NewAmsterdam Pharma	4	109.82 million	74.37 million	Optionable
VCEL Vericel	300	50.34 million	46.79 million	Optionable

MRVI, ARWR, VCEL, and NAMS Headlines

Recent News About These Companies

Vericel (NASDAQ:VCEL) Earns Overweight Rating from Stephens

May 25 at 3:15 AM | americanbankingnews.com

Vericel's (VCEL) Overweight Rating Reiterated at Stephens

May 24 at 9:42 AM | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AG

May 24 at 3:38 AM | marketbeat.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23 at 3:15 PM | benzinga.com

Vericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial Markets

May 23 at 3:16 AM | marketbeat.com

Rafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)

May 22 at 4:56 AM | marketbeat.com

Lazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)

May 22 at 4:15 AM | marketbeat.com

Soleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)

May 21, 2025 | marketbeat.com

Vericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Ameriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)

May 19, 2025 | marketbeat.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 17, 2025 | investing.com

Vericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by Brokerages

May 15, 2025 | marketbeat.com

StockNews.com Downgrades Vericel (NASDAQ:VCEL) to Sell

May 15, 2025 | marketbeat.com

Northern Trust Corp Buys 44,397 Shares of Vericel Co. (NASDAQ:VCEL)

May 13, 2025 | marketbeat.com

Leerink Partnrs Has Positive Outlook of Vericel Q4 Earnings

May 13, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Issues Earnings Results

May 12, 2025 | marketbeat.com

First Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL)

May 12, 2025 | marketbeat.com

Frontier Capital Management Co. LLC Has $15.82 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

May 11, 2025 | marketbeat.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?

May 10, 2025 | aaii.com

Hsbc Holdings PLC Acquires New Position in Vericel Co. (NASDAQ:VCEL)

May 10, 2025 | marketbeat.com

Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

May 9, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRVI, ARWR, VCEL, and NAMS Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.13 -0.26 (-1.69%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$15.32 +0.18 (+1.22%)

As of 05/23/2025 05:57 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Maravai LifeSciences NASDAQ:MRVI

$2.22 -0.08 (-3.48%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.22 +0.00 (+0.23%)

As of 05/23/2025 04:04 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

NewAmsterdam Pharma NASDAQ:NAMS

$17.61 -0.67 (-3.67%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$18.34 +0.73 (+4.12%)

As of 05/23/2025 07:56 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Vericel NASDAQ:VCEL

$40.92 -0.46 (-1.11%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$40.92 0.00 (0.00%)

As of 05/23/2025 06:09 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time